AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · Real-Time Price · USD
4.330
-0.230 (-5.04%)
At close: Apr 28, 2026, 4:00 PM EDT
4.410
+0.080 (1.85%)
After-hours: Apr 28, 2026, 5:57 PM EDT
AVITA Medical Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for AVITA Medical stock have an average target of 7.88, with a low estimate of 3.50 and a high estimate of 10. The average target predicts an increase of 81.99% from the current stock price of 4.33.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AVITA Medical stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 0 | 0 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +130.95% | Apr 9, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +130.95% | Apr 8, 2026 |
| Northland Capital Markets | Northland Capital Markets | Buy Initiates $10 | Buy | Initiates | $10 | +130.95% | Mar 5, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +130.95% | Feb 17, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +130.95% | Jan 26, 2026 |
Financial Forecast
Revenue This Year
83.90M
from 71.61M
Increased by 17.17%
Revenue Next Year
125.70M
from 83.90M
Increased by 49.82%
EPS This Year
-0.88
from -1.74
EPS Next Year
-0.75
from -0.88
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 88.9M | 263.6M | ||||||
| Avg | 83.9M | 125.7M | ||||||
| Low | 78.4M | 88.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 24.2% | 214.2% | ||||||
| Avg | 17.2% | 49.8% | ||||||
| Low | 9.5% | 5.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.19 | -0.02 | ||||||
| Avg | -0.88 | -0.75 | ||||||
| Low | -1.23 | -1.24 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.